ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment of CML with imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase inhibitor, has no significant influence on the inhibition of Hh pathway of CML-CP patients.